CYP2D6 and CYP2E1 Gene Polymorphisms and their Association with Cervical Cancer Susceptibility: A Hospital Based Case-Control Study from South-Western Maharashtra.
CYP2D6
CYP2E1
Cervical cancer
Genetic polymorphism
PCR-RFLP
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
received:
07
10
2021
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
1
9
2022
Statut:
epublish
Résumé
In last few years several studies all over the world discovered the genetic polymorphisms in different cytochrome P450 genes associated with risk of various cancers, but contradictory outcomes were evidenced in case of cervical cancer risk. In this case-control study we aimed to see whether the polymorphism of CYP2D6 or CYP2E1 genes may or may not be associated with cervical cancer risk in women of rural Maharashtra. In this case-control study, the association of CYP2D6 and CYP2E1 gene polymorphism with cervical cancer risk was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The study was conducted with 350 clinically confirmed cervical cancer patients and 350 healthy women in a population of South-Western Maharashtra. The Odds ratio (OR) with 95% confidence interval and p-value were evaluated, where p ≤0.005 was considered as statistically significant. After the analysis of SNP (rs389209) of CYP2D6 and SNPs (rs2031920, rs6413432, rs6413420) of CYP2E1, we noticed that variant allele A of CYP2E1*6 showed significant increase in cervical cancer cases (OR=4.81; 95% CI: 1.57- 14.77; p=0.005). The genotypic distribution of heterozygote G/A genotype of CYP2D6*4 showed negative association with cervical cancer development when age of cancer occurrence (OR=0.41; 95% CI: 0.27- 0.61; p<0.0001) and tobacco history (OR=0.35; 95% CI: 0.20- 0.59; p=0.0001) was considered. The findings from this study supported that rs6413432 SNP of CYP2E1*6 increased cervical cancer risk in the studied rural women population.
Sections du résumé
BACKGROUND
BACKGROUND
In last few years several studies all over the world discovered the genetic polymorphisms in different cytochrome P450 genes associated with risk of various cancers, but contradictory outcomes were evidenced in case of cervical cancer risk. In this case-control study we aimed to see whether the polymorphism of CYP2D6 or CYP2E1 genes may or may not be associated with cervical cancer risk in women of rural Maharashtra.
METHODS
METHODS
In this case-control study, the association of CYP2D6 and CYP2E1 gene polymorphism with cervical cancer risk was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The study was conducted with 350 clinically confirmed cervical cancer patients and 350 healthy women in a population of South-Western Maharashtra. The Odds ratio (OR) with 95% confidence interval and p-value were evaluated, where p ≤0.005 was considered as statistically significant.
RESULTS
RESULTS
After the analysis of SNP (rs389209) of CYP2D6 and SNPs (rs2031920, rs6413432, rs6413420) of CYP2E1, we noticed that variant allele A of CYP2E1*6 showed significant increase in cervical cancer cases (OR=4.81; 95% CI: 1.57- 14.77; p=0.005). The genotypic distribution of heterozygote G/A genotype of CYP2D6*4 showed negative association with cervical cancer development when age of cancer occurrence (OR=0.41; 95% CI: 0.27- 0.61; p<0.0001) and tobacco history (OR=0.35; 95% CI: 0.20- 0.59; p=0.0001) was considered.
CONCLUSION
CONCLUSIONS
The findings from this study supported that rs6413432 SNP of CYP2E1*6 increased cervical cancer risk in the studied rural women population.
Identifiants
pubmed: 36037111
doi: 10.31557/APJCP.2022.23.8.2591
pmc: PMC9741880
pii:
doi:
Substances chimiques
Cytochrome P-450 CYP2E1
EC 1.14.13.-
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2591-2597Références
Medicine (Baltimore). 2018 Mar;97(13):e0210
pubmed: 29595663
Medicine (Baltimore). 2018 Sep;97(39):e11910
pubmed: 30278485
Cancer Cell Int. 2017 Jan 7;17:11
pubmed: 28074086
Int J Gynecol Cancer. 2009 Nov;19(8):1300-2
pubmed: 20009880
Environ Toxicol Pharmacol. 2017 Jun;52:188-192
pubmed: 28433806
Asian Pac J Cancer Prev. 2011;12(6):1523-7
pubmed: 22126492
Oncotarget. 2017 Sep 18;8(49):86853-86864
pubmed: 29156840
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):785-90
pubmed: 14675315
Exp Ther Med. 2012 Nov;4(5):938-948
pubmed: 23226753
Drug Metab Lett. 2007 Dec;1(4):276-80
pubmed: 19356055
Cancer. 2000 May 1;88(9):2082-91
pubmed: 10813720
J Cancer Res Ther. 2012 Jan-Mar;8(1):40-5
pubmed: 22531512
Environ Mol Mutagen. 2003;41(1):69-76
pubmed: 12552594
Tumour Biol. 2013 Apr;34(2):1215-24
pubmed: 23355335
Indian J Med Res. 2018 Dec;148(6):687-696
pubmed: 30778002
Mol Clin Oncol. 2016 Jun;4(6):1031-1038
pubmed: 27284439
J Cell Mol Med. 2015 Sep;19(9):2136-42
pubmed: 25945422
Hum Genomics. 2011 Oct;5(6):530-7
pubmed: 22155602
Indian J Cancer. 2014 Apr-Jun;51(2):154-8
pubmed: 25104199
Eur J Obstet Gynecol Reprod Biol. 2014 May;176:68-74
pubmed: 24657182
Asian Pac J Cancer Prev. 2014;15(20):8815-22
pubmed: 25374213
Acta Oncol. 2014 Feb;53(2):195-200
pubmed: 24125101
Asian Pac J Cancer Prev. 2016;17(2):647-53
pubmed: 26925658
World J Gastroenterol. 2007 Nov 21;13(43):5725-30
pubmed: 17963298
Biomarkers. 2003 Sep-Oct;8(5):415-28
pubmed: 14602525